Last 12 months
Inside the activity.
0 purchase rows · 16 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 7 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 5 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 10, 2019 Filed Sep 12, 2019 17:55 UTC |
HAKAMI HOOMANEVP & Group President Diabetes
|
Exercise / conversionOrdinary Shares | 852 | $88.06 | $75,027.12 |
DisclosureSEC source: 0001127602-19-028265 · form4.xml · nonDerivative · entry 8 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,613 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 17:55 UTC |
HAKAMI HOOMANEVP & Group President Diabetes
|
SaleOrdinary Shares | 27,254 | $107.28 | $2,923,863.63 |
DisclosureSEC source: 0001127602-19-028265 · form4.xml · nonDerivative · entry 7 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,761 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $107.07 to $107.47, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 17:55 UTC |
HAKAMI HOOMANEVP & Group President Diabetes
|
Exercise / conversionOrdinary Shares | 27,254 | $88.06 | $2,399,987.24 |
DisclosureSEC source: 0001127602-19-028265 · form4.xml · nonDerivative · entry 6 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,015 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 17:55 UTC |
HAKAMI HOOMANEVP & Group President Diabetes
|
SaleOrdinary Shares | 321 | $107.22 | $34,417.62 |
DisclosureSEC source: 0001127602-19-028265 · form4.xml · nonDerivative · entry 5 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,761 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 17:55 UTC |
HAKAMI HOOMANEVP & Group President Diabetes
|
Exercise / conversionOrdinary Shares | 321 | $78.00 | $25,038.00 |
DisclosureSEC source: 0001127602-19-028265 · form4.xml · nonDerivative · entry 4 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,082 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 17:55 UTC |
HAKAMI HOOMANEVP & Group President Diabetes
|
SaleOrdinary Shares | 10,257 | $107.31 | $1,100,647.90 |
DisclosureSEC source: 0001127602-19-028265 · form4.xml · nonDerivative · entry 3 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,761 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $107.10 to $107.43, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 17:55 UTC |
HAKAMI HOOMANEVP & Group President Diabetes
|
Exercise / conversionOrdinary Shares | 10,257 | $78.00 | $800,046.00 |
DisclosureSEC source: 0001127602-19-028265 · form4.xml · nonDerivative · entry 2 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,018 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 17:55 UTC |
HAKAMI HOOMANEVP & Group President Diabetes
|
SaleOrdinary Shares | 10,000 | $107.09 | $1,070,850.00 |
DisclosureSEC source: 0001127602-19-028265 · form4.xml · nonDerivative · entry 1 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,761 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $107.00 to $107.39, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 05, 2019 Filed Aug 6, 2019 21:53 UTC |
Lerman Bradley ESVP General Counsel & Corp Sec
|
SaleOrdinary Shares | 4,000 | $100.31 | $401,240.00 |
DisclosureSEC source: 0001127602-19-026183 · form4.xml · nonDerivative · entry 1 Lerman Bradley E · CIK 0001559405 · SVP General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,906 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 02, 2019 Filed Aug 2, 2019 22:29 UTC |
Kuntz RichardSVP & Chief Medical & Science
|
SaleOrdinary Shares | 5,719 | $102.02 | $583,452.38 |
DisclosureSEC source: 0001127602-19-025932 · form4.xml · nonDerivative · entry 2 Kuntz Richard · CIK 0001341125 · SVP & Chief Medical & Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,241 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 02, 2019 Filed Aug 2, 2019 22:32 UTC |
Lerman Bradley ESVP General Counsel & Corp Sec
|
SaleOrdinary Shares | 6,599 | $102.02 | $673,229.98 |
DisclosureSEC source: 0001127602-19-025933 · form4.xml · nonDerivative · entry 2 Lerman Bradley E · CIK 0001559405 · SVP General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,906 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 01, 2019 Filed Aug 2, 2019 18:46 UTC |
WHITE ROBERT JOHNEVP & President MITG
|
Tax withholdingOrdinary Shares | 5,336 | $102.37 | $546,246.32 |
DisclosureSEC source: 0001127602-19-025941 · form4.xml · nonDerivative · entry 2 WHITE ROBERT JOHN · CIK 0001726709 · EVP & President MITG 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,917 Read SEC document |
| August 01, 2019 Filed Aug 2, 2019 18:46 UTC |
WHITE ROBERT JOHNEVP & President MITG
|
Tax withholdingOrdinary Shares | 2,846 | $102.37 | $291,345.02 |
DisclosureSEC source: 0001127602-19-025941 · form4.xml · nonDerivative · entry 1 WHITE ROBERT JOHN · CIK 0001726709 · EVP & President MITG 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,253 Read SEC document |
| August 01, 2019 Filed Aug 2, 2019 18:34 UTC |
Liddicoat John REVP & President of Americas
|
Tax withholdingOrdinary Shares | 8,298 | $102.37 | $849,466.26 |
DisclosureSEC source: 0001127602-19-025935 · form4.xml · nonDerivative · entry 2 Liddicoat John R · CIK 0001752060 · EVP & President of Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,111 Read SEC document |
| August 01, 2019 Filed Aug 2, 2019 18:34 UTC |
Liddicoat John REVP & President of Americas
|
Tax withholdingOrdinary Shares | 1,644 | $102.37 | $168,296.28 |
DisclosureSEC source: 0001127602-19-025935 · form4.xml · nonDerivative · entry 1 Liddicoat John R · CIK 0001752060 · EVP & President of Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,409 Read SEC document |
| August 01, 2019 Filed Aug 2, 2019 18:42 UTC |
Surface Carol ASVP, Chief HR Officer
|
Tax withholdingOrdinary Shares | 4,058 | $102.37 | $415,417.46 |
DisclosureSEC source: 0001127602-19-025939 · form4.xml · nonDerivative · entry 1 Surface Carol A · CIK 0001485966 · SVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,713 Read SEC document |
| August 01, 2019 Filed Aug 2, 2019 22:10 UTC |
COYLE MICHAEL JEVP & Group Pres, Cardiac&Vasc
|
Tax withholdingOrdinary Shares | 22,128 | $102.37 | $2,265,243.36 |
DisclosureSEC source: 0001127602-19-025929 · form4.xml · nonDerivative · entry 2 COYLE MICHAEL J · CIK 0001233311 · EVP & Group Pres, Cardiac&Vasc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,019 Read SEC document |
| August 01, 2019 Filed Aug 2, 2019 22:10 UTC |
COYLE MICHAEL JEVP & Group Pres, Cardiac&Vasc
|
Tax withholdingOrdinary Shares | 7,561 | $102.37 | $774,019.57 |
DisclosureSEC source: 0001127602-19-025929 · form4.xml · nonDerivative · entry 1 COYLE MICHAEL J · CIK 0001233311 · EVP & Group Pres, Cardiac&Vasc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,147 Read SEC document |
| August 01, 2019 Filed Aug 2, 2019 22:29 UTC |
Kuntz RichardSVP & Chief Medical & Science
|
Tax withholdingOrdinary Shares | 4,795 | $102.37 | $490,864.15 |
DisclosureSEC source: 0001127602-19-025932 · form4.xml · nonDerivative · entry 1 Kuntz Richard · CIK 0001341125 · SVP & Chief Medical & Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,960 Read SEC document |
| August 01, 2019 Filed Aug 2, 2019 22:25 UTC |
ISHRAK OMARDirector · Chairman & CEO
|
Tax withholdingOrdinary Shares | 24,894 | $102.37 | $2,548,398.78 |
DisclosureSEC source: 0001127602-19-025931 · form4.xml · nonDerivative · entry 1 ISHRAK OMAR · CIK 0001523102 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 598,708 Read SEC document |
| August 01, 2019 Filed Aug 2, 2019 22:37 UTC |
Martha GeoffreyEVP & GroupPres Restora Therap
|
Tax withholdingOrdinary Shares | 5,533 | $102.37 | $566,413.21 |
DisclosureSEC source: 0001127602-19-025936 · form4.xml · nonDerivative · entry 2 Martha Geoffrey · CIK 0001560409 · EVP & GroupPres Restora Therap 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,637 Read SEC document |
| August 01, 2019 Filed Aug 2, 2019 22:37 UTC |
Martha GeoffreyEVP & GroupPres Restora Therap
|
Tax withholdingOrdinary Shares | 4,242 | $102.37 | $434,253.54 |
DisclosureSEC source: 0001127602-19-025936 · form4.xml · nonDerivative · entry 1 Martha Geoffrey · CIK 0001560409 · EVP & GroupPres Restora Therap 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,170 Read SEC document |
| August 01, 2019 Filed Aug 2, 2019 22:39 UTC |
PARKHILL KAREN LEVP & Chief Financial Officer
|
Tax withholdingOrdinary Shares | 5,533 | $102.37 | $566,413.21 |
DisclosureSEC source: 0001127602-19-025937 · form4.xml · nonDerivative · entry 1 PARKHILL KAREN L · CIK 0001527660 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,392 Read SEC document |
| August 01, 2019 Filed Aug 2, 2019 18:44 UTC |
TEN HOEDT ROBEVP & President EMEA
|
Tax withholdingOrdinary Shares | 4,577 | $102.37 | $468,547.49 |
DisclosureSEC source: 0001127602-19-025940 · form4.xml · nonDerivative · entry 2 TEN HOEDT ROB · CIK 0001610036 · EVP & President EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,952 Read SEC document |
| August 01, 2019 Filed Aug 2, 2019 18:44 UTC |
TEN HOEDT ROBEVP & President EMEA
|
Tax withholdingOrdinary Shares | 3,510 | $102.37 | $359,318.70 |
DisclosureSEC source: 0001127602-19-025940 · form4.xml · nonDerivative · entry 1 TEN HOEDT ROB · CIK 0001610036 · EVP & President EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,529 Read SEC document |
| August 01, 2019 Filed Aug 2, 2019 22:32 UTC |
Lerman Bradley ESVP General Counsel & Corp Sec
|
Tax withholdingOrdinary Shares | 5,533 | $102.37 | $566,413.21 |
DisclosureSEC source: 0001127602-19-025933 · form4.xml · nonDerivative · entry 1 Lerman Bradley E · CIK 0001559405 · SVP General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,505 Read SEC document |
| August 01, 2019 Filed Aug 2, 2019 18:13 UTC |
HAKAMI HOOMANEVP & Group President Diabetes
|
Tax withholdingOrdinary Shares | 5,703 | $102.37 | $583,816.11 |
DisclosureSEC source: 0001127602-19-025930 · form4.xml · nonDerivative · entry 2 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,761 Read SEC document |
| August 01, 2019 Filed Aug 2, 2019 18:13 UTC |
HAKAMI HOOMANEVP & Group President Diabetes
|
Tax withholdingOrdinary Shares | 4,562 | $102.37 | $467,011.94 |
DisclosureSEC source: 0001127602-19-025930 · form4.xml · nonDerivative · entry 1 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,464 Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 18:01 UTC |
Liddicoat John REVP & President of Americas
|
GrantStock Option (Right to Buy) · Derivative | 1,615 | $0.00 Strike: $103.26 | $0.00 |
DisclosureSEC source: 0001127602-19-025557 · form4.xml · derivative · entry 3 Liddicoat John R · CIK 0001752060 · EVP & President of Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,615 Underlying: Ordinary Shares · 1,615 shares Expires 2029-07-29 F3 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 18:01 UTC |
Liddicoat John REVP & President of Americas
|
GrantStock Option (Right to Buy) · Derivative | 40,910 | $0.00 Strike: $103.26 | $0.00 |
DisclosureSEC source: 0001127602-19-025557 · form4.xml · derivative · entry 2 Liddicoat John R · CIK 0001752060 · EVP & President of Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,910 Underlying: Ordinary Shares · 40,910 shares Expires 2029-07-29 F3 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 18:01 UTC |
Liddicoat John REVP & President of Americas
|
GrantOrdinary Shares | 6,134 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-025557 · form4.xml · nonDerivative · entry 1 Liddicoat John R · CIK 0001752060 · EVP & President of Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,053 F1 · kind: The restrictions on these restricted stock units shall lapse 100% on the third anniversary of the Grant Date if the Company's cumulative non-GAAP diluted earnings per share ("EPS") growth during the 36-month period ending on the last day of the Company's fiscal year 2022 equals or exceeds a 3% cumulative compound annual growth rate, as determined by the Compensation Committee. F2 · balance_after: This balance increased by 876 shares due to exempt transactions such as dividend reinvestment and employee stock purchase plan. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 18:16 UTC |
WHITE ROBERT JOHNEVP & President MITG
|
GrantStock Option (Right to Buy) · Derivative | 1,615 | $0.00 Strike: $103.26 | $0.00 |
DisclosureSEC source: 0001127602-19-025566 · form4.xml · derivative · entry 3 WHITE ROBERT JOHN · CIK 0001726709 · EVP & President MITG 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,615 Underlying: Ordinary Shares · 1,615 shares Expires 2029-07-29 F3 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 18:16 UTC |
WHITE ROBERT JOHNEVP & President MITG
|
GrantStock Option (Right to Buy) · Derivative | 77,514 | $0.00 Strike: $103.26 | $0.00 |
DisclosureSEC source: 0001127602-19-025566 · form4.xml · derivative · entry 2 WHITE ROBERT JOHN · CIK 0001726709 · EVP & President MITG 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,514 Underlying: Ordinary Shares · 77,514 shares Expires 2029-07-29 F3 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 18:16 UTC |
WHITE ROBERT JOHNEVP & President MITG
|
GrantOrdinary Shares | 11,622 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-025566 · form4.xml · nonDerivative · entry 1 WHITE ROBERT JOHN · CIK 0001726709 · EVP & President MITG 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,099 F1 · kind: The restrictions on these restricted stock units shall lapse 100% on the third anniversary of the Grant Date if the Company's cumulative non-GAAP diluted earnings per share ("EPS") growth during the 36-month period ending on the last day of the Company's fiscal year 2022 equals or exceeds a 3% cumulative compound annual growth rate, as determined by the Compensation Committee. F2 · balance_after: This balance increased by 887 shares due to exempt transactions such as dividend reinvestment and employee stock purchase plan. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 18:11 UTC |
Surface Carol ASVP, Chief HR Officer
|
GrantStock Option (Right to Buy) · Derivative | 1,615 | $0.00 Strike: $103.26 | $0.00 |
DisclosureSEC source: 0001127602-19-025562 · form4.xml · derivative · entry 5 Surface Carol A · CIK 0001485966 · SVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,615 Underlying: Ordinary Shares · 1,615 shares Expires 2029-07-29 F3 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 18:11 UTC |
Surface Carol ASVP, Chief HR Officer
|
GrantStock Option (Right to Buy) · Derivative | 49,523 | $0.00 Strike: $103.26 | $0.00 |
DisclosureSEC source: 0001127602-19-025562 · form4.xml · derivative · entry 4 Surface Carol A · CIK 0001485966 · SVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,523 Underlying: Ordinary Shares · 49,523 shares Expires 2029-07-29 F3 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 18:11 UTC |
Surface Carol ASVP, Chief HR Officer
|
GrantOrdinary Shares | 7,425 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-025562 · form4.xml · nonDerivative · entry 1 Surface Carol A · CIK 0001485966 · SVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,771 F1 · kind: The restrictions on these restricted stock units shall lapse 100% on the third anniversary of the Grant Date if the Company's cumulative non-GAAP diluted earnings per share ("EPS") growth during the 36-month period ending on the last day of the Company's fiscal year 2022 equals or exceeds a 3% cumulative compound annual growth rate, as determined by the Compensation Committee. F2 · balance_after: This balance increased by 188 shares due to exempt transactions such as dividend reinvestment and employee stock purchase plan. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 21:45 UTC |
COYLE MICHAEL JEVP & Group Pres, Cardiac&Vasc
|
GrantStock Option (Right to Buy) · Derivative | 1,615 | $0.00 Strike: $103.26 | $0.00 |
DisclosureSEC source: 0001127602-19-025552 · form4.xml · derivative · entry 5 COYLE MICHAEL J · CIK 0001233311 · EVP & Group Pres, Cardiac&Vasc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,615 Underlying: Ordinary Shares · 1,615 shares Expires 2029-07-29 F4 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 21:45 UTC |
COYLE MICHAEL JEVP & Group Pres, Cardiac&Vasc
|
GrantStock Option (Right to Buy) · Derivative | 99,045 | $0.00 Strike: $103.26 | $0.00 |
DisclosureSEC source: 0001127602-19-025552 · form4.xml · derivative · entry 4 COYLE MICHAEL J · CIK 0001233311 · EVP & Group Pres, Cardiac&Vasc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,045 Underlying: Ordinary Shares · 99,045 shares Expires 2029-07-29 F4 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 21:45 UTC |
COYLE MICHAEL JEVP & Group Pres, Cardiac&Vasc
|
GrantOrdinary Shares | 14,850 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-025552 · form4.xml · nonDerivative · entry 1 COYLE MICHAEL J · CIK 0001233311 · EVP & Group Pres, Cardiac&Vasc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,708 F1 · kind: The restrictions on these restricted stock units shall lapse 100% on the third anniversary of the Grant Date if the Company's cumulative non-GAAP diluted earnings per share ("EPS") growth during the 36-month period ending on the last day of the Company's fiscal year 2022 equals or exceeds a 3% cumulative compound annual growth rate, as determined by the Compensation Committee. F2 · balance_after: This balance increased by 2,157 shares due to exempt transactions such as dividend reinvestment. F3 · balance_after: The number of shares beneficially owned includes 521 ordinary shares that were inadvertently omitted from Mr. Coyle's previous filings. The previously omitted shares were issued upon the conversion of 545 ordinary shares of Covidien plc that were held by Mr. Coyle at the time of the acquisition by Medtronic plc in January 2015. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 21:56 UTC |
Kuntz RichardSVP & Chief Medical & Science
|
GrantStock Option (Right to Buy) · Derivative | 1,615 | $0.00 Strike: $103.26 | $0.00 |
DisclosureSEC source: 0001127602-19-025555 · form4.xml · derivative · entry 3 Kuntz Richard · CIK 0001341125 · SVP & Chief Medical & Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,615 Underlying: Ordinary Shares · 1,615 shares Expires 2029-07-29 F3 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 21:56 UTC |
Kuntz RichardSVP & Chief Medical & Science
|
GrantStock Option (Right to Buy) · Derivative | 68,901 | $0.00 Strike: $103.26 | $0.00 |
DisclosureSEC source: 0001127602-19-025555 · form4.xml · derivative · entry 2 Kuntz Richard · CIK 0001341125 · SVP & Chief Medical & Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,901 Underlying: Ordinary Shares · 68,901 shares Expires 2029-07-29 F3 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 21:56 UTC |
Kuntz RichardSVP & Chief Medical & Science
|
GrantOrdinary Shares | 10,330 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-025555 · form4.xml · nonDerivative · entry 1 Kuntz Richard · CIK 0001341125 · SVP & Chief Medical & Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,755 F1 · kind: The restrictions on these restricted stock units shall lapse 100% on the third anniversary of the Grant Date if the Company's cumulative non-GAAP diluted earnings per share ("EPS") growth during the 36-month period ending on the last day of the Company's fiscal year 2022 equals or exceeds a 3% cumulative compound annual growth rate, as determined by the Compensation Committee. F2 · balance_after: This balance increased by 298 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 22:06 UTC |
PARKHILL KAREN LEVP & Chief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 1,615 | $0.00 Strike: $103.26 | $0.00 |
DisclosureSEC source: 0001127602-19-025560 · form4.xml · derivative · entry 6 PARKHILL KAREN L · CIK 0001527660 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,615 Underlying: Ordinary Shares · 1,615 shares Expires 2029-07-29 F3 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 22:06 UTC |
PARKHILL KAREN LEVP & Chief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 94,739 | $0.00 Strike: $103.26 | $0.00 |
DisclosureSEC source: 0001127602-19-025560 · form4.xml · derivative · entry 5 PARKHILL KAREN L · CIK 0001527660 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,739 Underlying: Ordinary Shares · 94,739 shares Expires 2029-07-29 F3 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 22:06 UTC |
PARKHILL KAREN LEVP & Chief Financial Officer
|
GrantOrdinary Shares | 14,204 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-025560 · form4.xml · nonDerivative · entry 1 PARKHILL KAREN L · CIK 0001527660 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,925 F1 · kind: The restrictions on these restricted stock units shall lapse 100% on the third anniversary of the Grant Date if the Company's cumulative non-GAAP diluted earnings per share ("EPS") growth during the 36-month period ending on the last day of the Company's fiscal year 2022 equals or exceeds a 3% cumulative compound annual growth rate, as determined by the Compensation Committee. F2 · balance_after: This balance increased by 214 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 21:53 UTC |
ISHRAK OMARDirector · Chairman & CEO
|
GrantStock Option (Right to Buy) · Derivative | 301,440 | $0.00 Strike: $103.26 | $0.00 |
DisclosureSEC source: 0001127602-19-025554 · form4.xml · derivative · entry 4 ISHRAK OMAR · CIK 0001523102 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,440 Underlying: Ordinary Shares · 301,440 shares Expires 2029-07-29 F3 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 21:53 UTC |
ISHRAK OMARDirector · Chairman & CEO
|
GrantOrdinary Shares | 45,194 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-025554 · form4.xml · nonDerivative · entry 1 ISHRAK OMAR · CIK 0001523102 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 623,602 F1 · kind: The restrictions on these restricted stock units shall lapse 100% on the third anniversary of the Grant Date if the Company's cumulative non-GAAP diluted earnings per share ("EPS") growth during the 36-month period ending on the last day of the Company's fiscal year 2022 equals or exceeds a 3% cumulative compound annual growth rate, as determined by the Compensation Committee. F2 · balance_after: This balance increased by 7,686 shares due to exempt transactions such as dividend reinvestment and employee stock purchase plan. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 21:59 UTC |
Lerman Bradley ESVP General Counsel & Corp Sec
|
GrantStock Option (Right to Buy) · Derivative | 1,615 | $0.00 Strike: $103.26 | $0.00 |
DisclosureSEC source: 0001127602-19-025556 · form4.xml · derivative · entry 3 Lerman Bradley E · CIK 0001559405 · SVP General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,615 Underlying: Ordinary Shares · 1,615 shares Expires 2029-07-29 F3 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 21:59 UTC |
Lerman Bradley ESVP General Counsel & Corp Sec
|
GrantStock Option (Right to Buy) · Derivative | 68,901 | $0.00 Strike: $103.26 | $0.00 |
DisclosureSEC source: 0001127602-19-025556 · form4.xml · derivative · entry 2 Lerman Bradley E · CIK 0001559405 · SVP General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,901 Underlying: Ordinary Shares · 68,901 shares Expires 2029-07-29 F3 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.